Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Other Operating Expenses (2017 - 2023)

Aptevo Therapeutics' Other Operating Expenses history spans 3 years, with the latest figure at $9.6 million for Q1 2023.

  • For Q1 2023, Other Operating Expenses changed N/A year-over-year to $9.6 million; the TTM value through Dec 2023 reached $9.6 million, changed N/A, while the annual FY2023 figure was $9.6 million, N/A changed from the prior year.
  • Other Operating Expenses for Q1 2023 was $9.6 million at Aptevo Therapeutics, down from $14.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $14.3 million in Q1 2020 and bottomed at $9.6 million in Q1 2023.